Novartis Receives European Commission Approval for Rhapsido®, the First Oral Targeted Therapy for Chronic Spontaneous Urticaria
Novartis has officially received European Commission (EC) approval for Rhapsido® (remibrutinib), marking a historic shift in the management of chronic spontaneous urticaria (CSU). Rhapsido...
A Global Pediatric Milestone: WHO Pre qualifies First Malaria Treatment for Newborns and Young Infants
In a landmark step for global child health, the World Health Organization (WHO) has prequalified the world’s first malaria treatment specifically designed for newborns...
Cipla Secures U.S. FDA Approval for First AB-Rated Generic Therapeutic Equivalent to Ventolin® HFA
The United States Food and Drug Administration (USFDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol,...
Johnson & Johnson to Acquire Atraverse Medical to Expand Cardiac Care Portfolio
Johnson & Johnson has entered into a definitive agreement to acquire Atraverse Medical, a medical device innovator focused on left-heart access technologies. The move...
New Hope for MOGAD Patients: ENSPRYNG Demonstrates Unparalleled 68% Reduction in Disabling Relapses
The Phase III METEOROID study, revealed ENSPRYNG (satralizumab) showing reduction in the risk of relapses by 68% in patients compared to placebo,according to...
India Expands COVID-19 Vaccine Portfolio with New Approvals Including Omicron JN.1 Variant Shot
India’s COVID-19 vaccination landscape continues to evolve, with the Central Drugs Standard Control Organization (CDSCO) releasing an updated list of approved vaccines as of...
